206 related articles for article (PubMed ID: 21143148)
1. Interferon-alpha in the treatment of multiple myeloma.
Khoo TL; Vangsted AJ; Joshua D; Gibson J
Curr Drug Targets; 2011 Mar; 12(3):437-46. PubMed ID: 21143148
[TBL] [Abstract][Full Text] [Related]
2. Role of alpha interferon in multiple myeloma.
Joshua DE; MacCallum S; Gibson J
Blood Rev; 1997 Dec; 11(4):191-200. PubMed ID: 9481449
[TBL] [Abstract][Full Text] [Related]
3. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
4. The role of alpha-interferon in multiple myeloma.
Peest D
Pathol Biol (Paris); 1999 Feb; 47(2):172-7. PubMed ID: 10192884
[TBL] [Abstract][Full Text] [Related]
5. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
Cooper MR
Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
[TBL] [Abstract][Full Text] [Related]
6. [Role of interferon for the treatment of myeloma].
Tomita S; Okamoto S
Nihon Rinsho; 2007 Dec; 65(12):2285-90. PubMed ID: 18069274
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
11. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
13. Management of myeloma: an Italian perspective.
Bruno B; Gay F; Boccadoro M; Palumbo A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
[TBL] [Abstract][Full Text] [Related]
14. Treatment of myeloma.
Smith ML; Newland AC
QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
[TBL] [Abstract][Full Text] [Related]
15. Interferon and multiple myeloma.
Lauta VM
Med Oncol; 1995 Mar; 12(1):63-9. PubMed ID: 8542250
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
17. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
19. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
20. Is Maintenance Therapy for Everyone?
Nooka AK; Lonial S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S139-44. PubMed ID: 27521311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
